Haemonetics Corporation
Financials
Valuation Metrics
Haemonetics Corporation's Market Cap is $4.93B. At end of 2025 it was $3.75B. Ranked #1373 of 3,121 in US market (top 44%), #900 of 1,658 on NYSE (top 54%), #86 of 205 in Health Care Equipment & Services (top 42%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.93B | US#1,373/3,121 Sec#86/205 |
| Revenue | $1.35B | US#1,702/3,121 Sec#106/205 |
| Net Income | $96M | US#1,636/3,121 Sec#83/205 |
| Total Assets | $2.37B | US#1,974/3,121 Sec#95/205 |
| Net Assets | $837M | US#1,886/3,121 Sec#98/205 |
| Employees | 3,023 | US#1,474/3,121 Sec#103/205 |
| Value | ||
| P/E | 51.22x | US#1,923/3,121 Sec#102/205 |
| P/B | 5.89x | US#2,336/3,121 Sec#144/205 |
| P/S | 3.65x | US#1,964/3,121 Sec#135/205 |
| EV/EBITDA | 22.52x | US#1,998/3,121 Sec#93/205 |
| FCF Yield | 5.91% | US#1,218/3,121 Sec#53/205 |
| Profitability | ||
| ROE | 11.50% | US#1,204/3,121 Sec#59/205 |
| ROA | 4.07% | US#1,219/3,121 Sec#80/205 |
| Op. Margin | 18.18% | US#1,011/3,121 Sec#31/205 |
| Revenue Growth | 0.44% | US#2,224/3,121 Sec#164/205 |
| Earnings Growth | -41.05% | US#1,692/3,121 Sec#89/205 |
| Financial Health | ||
| Debt Ratio | 182.57% | US#1,700/3,121 Sec#146/205 |
| Total Debt | $1.17B | US#1,463/3,121 Sec#79/205 |
| FCF | $291M | US#1,183/3,121 Sec#69/205 |
| Cash | $223M | US#1,649/3,121 Sec#95/205 |
| Current Ratio | 3.08x | US#767/3,121 Sec#76/205 |
| Net Debt/EBITDA | 3.64x | US#1,764/3,121 Sec#114/205 |
| Performance | ||
| 1Y Return | 112.14% | US#171/3,121 Sec#16/205 |
| 1M Return | 0.09% | US#649/3,121 Sec#74/205 |
| From 52W High | -1.62% | US#110/3,121 Sec#19/205 |
| 1Y MDD | -40.06% | US#2,017/3,121 Sec#116/205 |
| Trading | ||
| Volume | 662,256 shares | US#2,004/3,121 Sec#142/205 |
| Trading Value | $72M | US#1,194/3,121 Sec#89/205 |
| Per Share | ||
| EPS | $2.12 | US#1,298/3,121 Sec#66/205 |
| BPS | $18.42 | US#1,321/3,121 Sec#74/205 |
Company Info
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.